Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: A cost-effectiveness analysis

BMC Nephrology

Volumn 8, Issue , 2007, Pages

  Littlewood, Kavi J ^a   Greiner, Wolfgang ^b   Baum, Dominique ^c   Zoellner, York ^c  

^a MAPI GROUP   (Netherlands)

^b BIELEFELD UNIVERSITY   (Germany)

^c Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; LOSARTAN; MOXONIDINE; NITRENDIPINE; IMIDAZOLE DERIVATIVE;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIAC PATIENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HEALTH CARE; HEALTH CARE COST; HUMAN; HYPERTENSION; KIDNEY FAILURE; LONG TERM CARE; OUTCOME ASSESSMENT; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICAL MODEL; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; NETHERLANDS; PREDICTION AND FORECASTING; PROBABILITY; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; RENOVASCULAR HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HUMANS; HYPERTENSION, RENAL; IMIDAZOLES; KIDNEY FAILURE, CHRONIC; MARKOV CHAINS; MODELS, STATISTICAL; NATIONAL HEALTH PROGRAMS; NETHERLANDS; NITRENDIPINE; PREDICTIVE VALUE OF TESTS;

EID: 34548559605     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-8-9     Document Type: Article

References (30)

1. De maatschappelijke kosten van nierziekten in Nederland. GA De Wit JJ Polder KJ Jager FTh De Charro, TSG 2001 79 49 54
2. Blood pressure and end-stage renal disease in men. MJ Klag PK Whelton BL Randall JD Neaton FL Brancati CE Ford NB Shulman J Stamler, N Engl J Med 334 1 13 8 1996 Jan 4 10.1056/NEJM199601043340103 7494564
3. Progression of chronic renal failure. HT Yu, Arch Intern Med 163 12 1417 29 2003 Jun 23 10.1001/archinte.163.12.1417 12824091
4. What is the optimal strategy to intensify blood pressure control and prevent progression off renal failure. M Epstein S Tobe, Curr Hypertens Rep 2001 3 5 422 8 10.1007/s11906-001-0061-3 11551378
5. Audit of antihypertensive treatment in patients with renal failure. Schwenger E Ritz, Nephrol Dial Transplant 1998 13 12 3091 5 10.1093/ndt/13.12. 3091 9870471
6. The role of sympathetic nervous activity in chronic renal failure. LC Rump, Journal of Clinical and Basic Cardiology 2001 4 3 179 182
7. Renal parenchymal hypertension: current concepts of pathogenesis and management. RA Preston I Singer M Epstein, Arch Intern Med 156 6 602 11 1996 Mar 25 10.1001/archinte.156.6.602 8629871
8. Sympathetic overactivity in patients with chronic renal failure. RL Converse TN Jacobson RD Toto CM Jost F Cosentino F Fouad-Tarazi RG Victor, N Engl J Med 1992 327 27 1912 8 1454086
9. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Neumann G Ligtenberg L Oey H Koomans PJ Blankestijn, J Am Soc Nephrol 2004 15 2902 7 10.1097/01.ASN.0000143471. 10750.8C 15504943
10. Moxonidine treatment of hypertensive patients with advanced renal failure. O Vonend P Marsalek H Russ R Wulkow V Oberhauser LC Rump, J Hypertens 2003 21 9 1709 17 10.1097/00004872-200309000-00021 12923404
11. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. P Ruggenenti A Perna G Gherardi G Garini C Zoccali M Salvadori F Scolari FP Schena G Remuzzi, Lancet 1999 354 359 64 10.1016/S0140-6736(98)10363-X 10437863
12. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group, Lancet 1997 349 1857 63 10.1016/S0140-6736(96)11445-8 9217756
13. Renoprotective effect of the angiotensin-receptor antagonist irbesartan inpatients with nephropathy due to type 2 diabetes. EJ Lewis LG Hunsicker WR Clarke T Berl MA Pohl JB Lewis E Ritz RC Atkins R Rohde I Raz, N Engl J Med 2001 345 12 851 60 10.1056/NEJMoa011303 11565517
14. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. I Giatras J Lau AS Levey, Ann Intern Med 127 5 337 45 1997 Sep 1 9273824
15. Measurement of renal function, when to refer and when to start dialysis. ERA Guideline 1.3, Nephrol Dial Transplant 2002 17 10 11
16. US National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF/DOQI). http://www.kidney.org/professionals/kdoqi/index.cfm Accessed 25 July 2005
17. Estimation of GFR. ERA guideline. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease, Nephrol Dial Transplant 2002 17 Suppl 7 7 15 12386205
18. Cálculo de probabilidades y Estadística. H Fernández-Abascal MM Guijarro JL Rojo JA Sanz, Ed. Ariel, Barcelona (Spain) 1994
19. Distributions in Statistics. NL Johnson, 1992, 1994, 1997. Copyright 2001 JL Rojo J. Wiley y Houghton M. Co 1-4
20. ERA EDTA Annual report. 2002 http://www.era-edta-reg.org/files/ annualreports/pdf/AnnRep2002.pdf Accessed 25 July 2005
21. Economic evaluation of benazepril in chronic renal insufficiency. BA van Hout GP Simeon J McDonnell JF Mann, Kidney Int Suppl 1997 63 S159 62 9407447
22. Economic evaluation of end stage renal disease treatment. GA de Wit PG Ramsteijn FT de Charro, Health Policy 1998 44 3 215 32 10.1016/S0168-8510(98) 00017-7 10182294
23. OECD. http://www.oecd.org Accessed 25 July 2005
24. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. JB Oostenbrink CAM Bouwmans MA Koopmanschap FFH Rutten, College voor Zorgverzekeringen. Geactualiseerde versie 2004
25. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. S Klahr AS Levey GJ Beck AW Caggiula L Hunsicker JW Kusek G Striker, N Engl J Med 330 13 877 84 1994 Mar 31 10.1056/NEJM199403313301301 8114857
26. The renoprotective effect of combined antihypertensive drugs. L Del Vecchio F Locatelli, J Nephrol 2001 14 1 7 14 11281347
27. Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies? F Locatelli L Del Vecchio M D'Amico S Andrulli, J Am Soc Nephrol 2002 13 Suppl 3 S196 201 10.1097/01.ASN.0000032521. 12410.29 12466314
28. Should Hepatitis C-infected kidneys be transplanted in the United States? BA Kiberd, Transplantation 1994 57 7 1068 72 10.1097/00007890-199404150-00015 8165705
29. The cost-effectiveness of early surgery versus watchful waiting in the management of small abdominal aortic aneurysms. DA Katz JL Cronenwett, J Vasc S 1994 19 6 980 90
30. The renal arterial resistance index and renal allograft survival. J Radermacher M Mengel S Ellis S Stuht M Hiss A Schwarz U Eisenberger M Burg FC Luft W Gwinner H Haller, N Engl J Med 349 2 115 24 2003 Jul 10 10.1056/NEJMoa022602 12853584